BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 36331291)

  • 1. Pyrotinib-based treatments in HER2-positive breast cancer patients with brain metastases.
    Ma X; Li Y; Li L; Gao C; Liu D; Li H; Zhao Z; Zhao B
    Ann Med; 2022 Dec; 54(1):3085-3095. PubMed ID: 36331291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pyrotinib combining with radiotherapy on breast cancer with brain metastasis.
    Ma X; Li Y; Zhao Z; Li L; Gao C; Liu D; Li B; Zhao B
    Exp Biol Med (Maywood); 2023 Jan; 248(2):106-116. PubMed ID: 36533572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Data of Pyrotinib-Based Therapy in Metastatic HER2-Positive Breast Cancer: Promising Efficacy in Lapatinib-Treated Patients and in Brain Metastasis.
    Lin Y; Lin M; Zhang J; Wang B; Tao Z; Du Y; Zhang S; Cao J; Wang L; Hu X
    Cancer Res Treat; 2020 Oct; 52(4):1059-1066. PubMed ID: 32340083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Efficacy and Safety of Inetetamab and Pyrotinib in Combination with Vinorelbine for Second-line Therapy and Beyond in HER2-positive Metastatic Breast Cancer: A Single-institution Clinical Experience.
    Wu F; Chen M; Wang L; Li N; Wu X; Chen X; Hong Y; Li C; Lin L; Chen K; Huang W; Liu J
    Curr Cancer Drug Targets; 2024; 24(5):490-500. PubMed ID: 37916639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intracranial Efficacy of Pyrotinib and Capecitabine Combination Therapy in HER2-Positive Breast Cancer with Brain Metastases.
    Wang C; Xiang J; Zhang Q; Li J; Liu Y; Liu J
    Drug Des Devel Ther; 2024; 18():909-917. PubMed ID: 38545432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy and safety of trastuzumab and albumin-bound paclitaxel with or without pyrotinib as neoadjuvant therapy for HER2-positive breast cancer: a prospective observational cohort study.
    Wang Y; Xu Y; Liu X; Li C; Wang J; Zhang X; Shao B; Zhang J
    Gland Surg; 2024 May; 13(5):654-662. PubMed ID: 38845840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term Outcome Analysis of Pyrotinib in Patients With HER2-Positive Metastatic Breast Cancer and Brain Metastasis: A Real-World Study.
    Liang X; Gui X; Yan Y; Di L; Liu X; Li H; Song G
    Oncologist; 2024 Feb; 29(2):e198-e205. PubMed ID: 37589217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy study of oral metronomic vinorelbine combined with trastuzumab (mNH) in HER2-positive metastatic breast cancer: a phase II trial.
    Wang Z; Liu J; Ma F; Wang J; Luo Y; Fan Y; Yuan P; Zhang P; Li Q; Li Q; Xu B
    Breast Cancer Res Treat; 2021 Jul; 188(2):441-447. PubMed ID: 33895900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pyrotinib Combined With Vinorelbine in HER2-Positive Metastatic Breast Cancer: A Multicenter Retrospective Study.
    Li Y; Qiu Y; Li H; Luo T; Li W; Wang H; Shao B; Wang B; Ge R
    Front Oncol; 2021; 11():664429. PubMed ID: 33996589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, Efficacy, and Biomarker Analysis of Pyrotinib in Combination with Capecitabine in HER2-Positive Metastatic Breast Cancer Patients: A Phase I Clinical Trial.
    Li Q; Guan X; Chen S; Yi Z; Lan B; Xing P; Fan Y; Wang J; Luo Y; Yuan P; Cai R; Zhang P; Li Q; Zhong D; Zhang Y; Zou J; Zhu X; Ma F; Xu B
    Clin Cancer Res; 2019 Sep; 25(17):5212-5220. PubMed ID: 31138588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Efficacy and safety of oral pyrotinib in HER2 positive metastatic breast cancer: real-world practice].
    Song GH; Li HP; DI LJ; Yan Y; Jiang HF; Xu L; Wan DG; Li Y; Wang MP; Xiao Y; Zhang RY; Ran R; Wang H
    Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Apr; 52(2):254-260. PubMed ID: 32306007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brain Radiotherapy With Pyrotinib and Capecitabine in Patients With ERBB2-Positive Advanced Breast Cancer and Brain Metastases: A Nonrandomized Phase 2 Trial.
    Yang Z; Meng J; Mei X; Mo M; Xiao Q; Han X; Zhang L; Shi W; Chen X; Ma J; Palmer J; Shao Z; Zhang Z; Yu X; Guo X
    JAMA Oncol; 2024 Mar; 10(3):335-341. PubMed ID: 38175627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HER2-targeted regimens after prior trastuzumab for patients with HER2-positive unresectable, locally advanced or metastatic breast cancer: a network meta-analysis of randomized controlled trials.
    Li X; Wu S; Zhang L; Zhu J; Xu B
    Ann Transl Med; 2020 Dec; 8(24):1634. PubMed ID: 33490146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pyrotinib or Lapatinib Combined With Capecitabine in HER2-Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study.
    Ma F; Ouyang Q; Li W; Jiang Z; Tong Z; Liu Y; Li H; Yu S; Feng J; Wang S; Hu X; Zou J; Zhu X; Xu B
    J Clin Oncol; 2019 Oct; 37(29):2610-2619. PubMed ID: 31430226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pyrotinib versus lapatinib therapy for HER2 positive metastatic breast cancer patients after first-line treatment failure: A meta-analysis and systematic review.
    Yuan Y; Liu X; Cai Y; Li W
    PLoS One; 2023; 18(1):e0279775. PubMed ID: 36602979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy study of oral metronomic capecitabine combined with pyrotinib in HER2-positive metastatic breast cancer: A phase II trial.
    He M; Liu J; Wang Z; Ma F; Wang J; Zhang P; Li Q; Yuan P; Luo Y; Fan Y; Mo H; Lan B; Li Q; Xu B
    Breast; 2023 Dec; 72():103581. PubMed ID: 37742492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pyrotinib Combined with Vinorelbine in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer: A Multicenter, Single-Arm, Prospective Study.
    Jiang K; Hong R; Xia W; Lu Q; Li L; Huang J; Shi Y; Yuan Z; Zheng Q; An X; Xue C; Huang J; Bi X; Chen M; Zhang J; Xu F; Wang S
    Cancer Res Treat; 2024 Apr; 56(2):513-521. PubMed ID: 37846468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of pyrotinib-containing regimen in the patients with HER2-positive metastatic breast cancer: A multicenter real-world study.
    Yin S; Chi Y; Du Y; Wang J; Shan C; Yi W; Shang M; Man X; Tan Q; Li H
    Cancer Med; 2023 Feb; 12(3):2333-2344. PubMed ID: 35894763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pyrotinib Treatment in Patients With HER2-positive Metastatic Breast Cancer and Brain Metastasis: Exploratory Final Analysis of Real-World, Multicenter Data.
    Anwar M; Chen Q; Ouyang D; Wang S; Xie N; Ouyang Q; Fan P; Qian L; Chen G; Zhou E; Guo L; Gu X; Ding B; Yang X; Liu L; Deng C; Xiao Z; Li J; Wang Y; Zeng S; Hu J; Zhou W; Qiu B; Wang Z; Weng J; Liu M; Li Y; Tang T; Wang J; Zhang H; Dai B; Tang W; Wu T; Xiao M; Li X; Liu H; Li L; Yi W
    Clin Cancer Res; 2021 Aug; 27(16):4634-4641. PubMed ID: 34112711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and safety of pyrotinib-based therapy in patients with HER2-positive metastatic breast cancer: A real-world retrospective study.
    Li C; Bian X; Liu Z; Wang X; Song X; Zhao W; Liu Y; Yu Z
    Cancer Med; 2021 Dec; 10(23):8352-8364. PubMed ID: 34672424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.